

# ALASKA STATE LEGISLATURE

## Session

State Capitol, Rm. 418  
Juneau, AK 99801  
(907) 465-3892  
Fax: (907) 465-6595

## Interim

1500 W. Benson Blvd.  
Anchorage, AK 99503  
(907) 269-0234  
Fax: (907) 269-0238



House Finance Committee

Dept. of Law  
Finance Subcommittee  
*Chairman*

Dept. of Administration  
Finance Subcommittee  
*Chairman*

Rep.Jason.Grenn@akleg.gov

## REPRESENTATIVE JASON GRENN

### EXPLANATION OF CHANGES

#### House Bill 43

#### Version D to Version J

1. **Page 1, Line 2 following “ill”:** Inserts “for the purpose of sustaining the patient’s life”

Amends the bill title to clarify the use of investigational treatments by terminally ill patients must be for life-sustaining purposes.

2. **Page 1, Line 10 following “patient”:** Inserts “for the purpose of sustaining the patient’s life”

Clarifies that prescribing, dispensing or administering investigational drugs to terminally ill patients by a physician must be for life-sustaining purposes.

3. **Page 2, Line 11 following “Phase 3”:** Inserts “or is in the new drug application process following Phase 3 of clinical trials”

Amends the definition of “investigational drug, biological product, or device” to encompass investigational treatments that have passed Phase 3 of the FDA approval process, but are still not fully approved. This change ensures access to investigational treatments is continuous between Phase 1 and final approval by the FDA, with no gap during the marketing approval phase of the process.

4. **Page 2, Line 21 following “device”:** Inserts “for the purpose of sustaining the patient’s life”

Clarifies the use of investigational treatments by terminally ill patients must be for life-sustaining purposes.